CMBA
BPMC

C.M. Bidwell & Associates’s Blueprint Medicines BPMC Stock Holding History

C.M. Bidwell & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-838
Closed -$73.1K – 452
2024
Q4 		$73.1K Buy
838
+11
+1% +$1.01K 0.04% 202
2024
Q3 		$76.5K Buy
827
+449
+119% +$44.6K 0.05% 198
2024
Q2 		$40.7K Buy
+378
New +$37.8K 0.03% 238

Other funds holding BPMC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

C.M. Bidwell & Associates's BPMC Position: Q1 2025 in Review

C.M. Bidwell & Associates sold out of Blueprint Medicines (BPMC) in Q1 2025, closing a stake of 838 shares — an estimated $73.1K sold.

C.M. Bidwell & Associates first reported a position in BPMC in Q2 2024 and held it in 3 quarters. The position peaked at $76.5K in Q3 2024. 352 funds tracked by Wall St. Rank hold BPMC as of Q1 2025.

  • C.M. Bidwell & Associates reported no remaining Blueprint Medicines position as of Q1 2025 after selling out during the quarter.
  • C.M. Bidwell & Associates sold 838 Blueprint Medicines shares in Q1 2025, an estimated $73.1K.
  • C.M. Bidwell & Associates first reported a position in Blueprint Medicines in Q2 2024 and held it in 3 quarters.
  • C.M. Bidwell & Associates's Blueprint Medicines position peaked at $76.5K in Q3 2024.
  • 352 funds tracked by Wall St. Rank held Blueprint Medicines as of Q1 2025.

Based on C.M. Bidwell & Associates's 13F filing for Q1 2025, filed 15 May 2025.